Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01119287 · ClinicalTrials.gov registry record · Phase 4
Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis
A Phase 4 study of Allergic Conjunctivitis, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 180
- Enrollment target
- 1
- Study location
NCT01119287 is a Phase 4 study of Allergic Conjunctivitis that has completed, run by Alcon Research. The registered enrollment target is 180 participants, above the 126-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (43% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01119287, a Phase 4 study of Allergic Conjunctivitis, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study was to evaluate the efficacy of Maxidex and Patanol compared to placebo in patients with allergic conjunctivitis when exposed to controlled allergen levels in an Environmental Exposure Chamber (EEC).
Conditions Studied
Interventions
- DRUG Dexamethasone 0.1% ophthalmic suspension
- DRUG Olopatadine hydrochloride 0.1% ophthalmic solution
- OTHER Inactive ingredients, used as placebo
Study Locations (1)
Texas
- Contact Alcon Call Center For Trial Locations - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01119287
The ClinicalTrials.gov registry entry for NCT01119287 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 126-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (43% higher). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Conjunctivitis appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone 0.1% ophthalmic suspension is the first listed.
NCT01119287 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01119287 about?
NCT01119287 is a clinical study titled "Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis". The purpose of this study was to evaluate the efficacy of Maxidex and Patanol compared to placebo in patients with allergic conjunctivitis when exposed to controlled allergen levels in an Environmental Exposure Chamber (EEC).
What is the current status of trial NCT01119287?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 180 participants. The study started on 2010-03. Estimated completion is 2010-09.
What conditions does trial NCT01119287 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis.
What interventions are being tested in trial NCT01119287?
The interventions under investigation include: Dexamethasone 0.1% ophthalmic suspension (DRUG), Olopatadine hydrochloride 0.1% ophthalmic solution (DRUG), Inactive ingredients, used as placebo (OTHER).
Who is sponsoring clinical trial NCT01119287?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01119287 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Alcon's Ocular Image Quantification System
COMPLETED · Phase 4
-
A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis
COMPLETED · Phase 4
-
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
COMPLETED · Phase 4
-
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
COMPLETED · Phase 4
-
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
RECRUITING · Phase 2
-
Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.